Pacira to invest up to $25m in surgical reconstruction company

Pacira Pharmaceuticals (NSDQ:PCRX) plans to invest up to $25 million in privately-held surgical reconstruction company Tela Bio, the company said today.

Pennsylvania-based Tela Bio has a portfolio of reinforced bioscaffold products, called OviTex, which combine biologic and synthetic materials in an embroidered implant that allows fluid and cells to move freely through the device. The implants are designed for ventral hernia repair and abdominal wall reconstruction.

Get the full story at our sister site, Drug Delivery Business News.

The post Pacira to invest up to $25m in surgical reconstruction company appeared first on MassDevice.

from MassDevice http://ift.tt/2y3mlq9